LATEST PRESS RELEASE

Amorfix presents scientific update for its Alzheimer's disease diagnostic at Alzheimer's disease conference

July 17, 2014

View

Amorfix awarded broad United States patent for misfolded SOD1-targeted treatment of ALS

July 16, 2014

View

Amorfix announces fiscal 2014 year end results

June 13, 2014

View

William Wyman appointed Amorfix chairman of the board

June 12, 2014

View

View All Amorfix Press Releases

TSX:AMF listed

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including ALS, cancer, and Alzheimer's Disease.

Amorfix is a pioneer in the ability to identify unique regions that are buried in normal proteins, and exposed to antibodies when proteins are aberrantly folded. These unique regions are designated Disease Specific Epitopes™ (DSE), which can be exploited by Amorfix to develop highly specific diagnostic tools, as well as targets for therapeutics of protein misfolding diseases.

amorfix life sciences